Fewer Drug Launches In 2022, But Standouts Among Them

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Coartem Baby to be rolled out in eight African countries in the autumn.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.